Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...
The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback